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Abstract
Background: Tumor cell death generates products that can be measured in the circulation of
cancer patients. CK18-Asp396 (M30 antigen) is a caspase-degraded product of cytokeratin 18
(CK18), produced by apoptotic epithelial cells, and is elevated in breast and lung cancer patients.
Methods: We determined the CK18-Asp396 and total CK18 levels in plasma of 49 colorectal
cancer patients, before and after surgical resection of the tumor, by ELISA. Correlations with
patient and tumor characteristics were determined by Kruskal-Wallis H and Mann-Whitney U
tests. Disease-free survival was determined using Kaplan-Meier methodology with Log Rank tests,
and univariate and multivariate Cox proportional hazard analysis.
Results: Plasma CK18-Asp396 and total CK18 levels in colorectal cancer patients were related to
disease stage and tumor diameter, and were predictive of disease-free survival, independent of
disease-stage, with hazard ratios (HR) of patients with high levels (> median) compared to those
with low levels (≤ median) of 3.58 (95% CI: 1.17–11.02) and 3.58 (95% CI: 0.97–7.71), respectively.
The CK18-Asp396/CK18 ratio, which decreased with tumor progression, was also predictive of
disease-free survival, with a low ratio (≤ median) associated with worse disease-free survival: HR
2.78 (95% CI: 1.06–7.19). Remarkably, the plasma CK18-Asp396 and total CK18 levels after
surgical removal of the tumor were also predictive of disease-free survival, with patients with high
levels having a HR of 3.78 (95% CI: 0.77–18.50) and 4.12 (95% CI: 0.84–20.34), respectively,
indicating that these parameters can be used also to monitor patients after surgery.
Conclusion: CK18-Asp396 and total CK18 levels in the circulation of colorectal cancer patients
are predictive of tumor progression and prognosis and might be helpful for treatment selection and
monitoring of these patients.
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Background
Death of tumor cells generates detectable protein prod-
ucts in the patient's circulation, which may be used for
cancer diagnostics and/or monitoring of therapy effi-
cacy[1]. Apoptosis is a form of regulated cell death that is
characterized by specific structural changes, mediated by
proteases of the caspase family [2]. Caspase activity itself
or the presence of specific degradation products can be
used for the detection of tumor cell apoptosis.
The M30 antibody detects a caspase-degraded product,
CK18-Asp396, of the important cytoskeletal protein
cytokeratin 18 (CK18) of epithelial cells, which is
expressed by most carcinomas, including those of breast,
prostate, lung and colon [3]. Immunohistochemistry with
the M30 antibody has been shown to be as specific as the
morphological detection or TdT-mediated dUTP-biotin
nick end-labelling (TUNEL) technique to establish of
apoptosis in tissue [3-5]. Importantly, the levels of CK18-
Asp396 can also be determined in the circulation by a spe-
cific ELISA, allowing the detection of tumor cell apoptosis
in the serum/plasma of cancer patients [6,7]. However,
CK18-Asp396 detection in the plasma is not tumor spe-
cific, healthy controls have background levels, due to
apoptosis of normal epithelial cells. Circulating CK18-
Asp396 levels were found to be elevated in patients with
lung and breast cancer, and were predictive to survival or
recurrence outcome [8,9]. In addition, circulating CK18-
Asp396 levels increased shortly after chemotherapy in
hormone-refractory prostate cancer and lung cancer,
implying that this was a result of chemotherapy-induced
tumor cell apoptosis [9-11].
During non-programmed cell death, i.e., necrosis, intact
CK18 of epithelial tumor cells is released into the circula-
tion, which can be measured by a total CK18 ELISA, that
also detects the CK18-Asp396 [11]. Cytokeratins and their
cleaved forms are secreted in aggregates into the circula-
tion and both CK18-Asp396 and total CK18 levels in
human plasma samples have a long-term stability when
stored at -80°C [12].
The ratio between CK18-Asp396 and total CK18 levels in
the circulation depends on the balance between caspase-
mediated apoptosis and non-proteolytic necrosis. This
balance might be an important factor and denominator to
select patient for treatment that induces necrosis vs treat-
ment that increases apoptosis. For instance, docetaxel
treatment increased levels of CK18-Asp396 in the serum
of breast cancer patients, indicating apoptotic death of
tumor cells, while cyclophosphamide/epirubicin/5-fluor-
ouracil treatment increased total CK18 levels, indicating
necrotic death of tumor cells [13]. The increase of total
CK18 serum levels correlated to the clinical therapy
response [13]. The CK18-Asp396/CK18 ratio was shown
to be decreased, i.e., more necrosis over apoptosis, in
endometrial cancer stage III/IV when compared with stage
II, indicating less apoptosis and/or more necrosis during
tumor progression [11]. In the present study, we deter-
mined the CK18-Asp396 and total CK18 levels in plasma
of 49 colorectal cancer patients and found these levels to
predict clinical outcome of these patients.
Methods
Patients, plasma and tissue collection
The study population consisted of 49 colorectal cancer
patients that did not receive pre-operative treatment and
had been admitted to the Leiden University Medical Cen-
tre for surgical resection. Citrate plasma samples were col-
lected, with informed consent of the patients, before
resection (P1, pre-operative), shortly after surgical resec-
tion (P2) and about 4.5 months after the operation (P3,
post-operative), when feasible. Citrate plasma samples
were collected before 9.00 a.m. under fasting conditions
and stored at -70°C. Fresh tissue was collected from the
surgical specimens immediately after resection, and atten-
tion was paid to collect material from the non-necrotic
part of the tumor. Normal mucosa samples were obtained
at a distance of approximately 10 cm from the tumor. Tis-
sue samples were also frozen and stored at -70°C until
use. Macroscopic (diameter and localization of the
tumor) as well as microscopic data were assessed, includ-
ing classification according to the WHO. Colonic cancers
were classified as being proximal or distal to, and includ-
ing, the splenic flexure. Follow-up information, including
post-operative adjuvant therapy, was available for a
period up to 8 years. The study was performed according
to the guidelines of the Medical Ethics Committee of the
Leiden University Medical Centre in compliance with the
Helsinki Declaration.
Tissue homogenization and protein determination
Frozen tissue specimens were weighed and homogenized
on ice for 2 minutes in 1 ml Tris-HCl, 0.1% Tween 80, pH
7.5 per 60 mg tissue using a Potter device (B Braun, Ger-
many), and centrifuged twice at 8000 × g for 2.5 min at
4°C. Protein content was measured according to Lowry et
al. and standardized by bovine serum albumin [14].
CK18-Asp396 and total CK18 detection
For the detection of CK18-Asp396 and total CK18 in the
plasma of colorectal cancer patients commercially available
immunosorbent sandwich ELISAs were used, according to
manufacturer's instructions (M30-apoptosense ELISA and
M65 ELISA, Peviva, Sweden). For the determination of
CK18-Asp396 and total CK18 levels in tissues 1 μg/μl pro-
tein homogenates were diluted up to 1000 times, depend-
ent on antigen levels. The antigen levels in the plasma were
expressed as U/L and antigen levels in tumor tissue or nor-
mal mucosa were expressed as U/mg protein.BMC Cancer 2009, 9:88 http://www.biomedcentral.com/1471-2407/9/88
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Statistical analysis
Statistical analysis was performed with Statistical Package
for Social Sciences (SPSS) statistical software (version 12.0
for Windows, SPSS Inc, Chicago, IL). For relations
between CK18-Asp396 or total CK18 antigen levels in P1,
P2 and P3 Spearman correlation and Wilcoxon signed-
rank tests were used. For the relation with patient charac-
teristics non-parametric Spearman correlation, Kruskal-
Wallis H and Mann-Whitney U tests were used, because
the study parameters did not follow a normal distribu-
tion. Disease-free survival was estimated using Kaplan-
Meier methodology with cancer-related death and local or
distant recurrence as events, dichotomized for CK18-
Asp396, total CK18 or CK18-Asp396/CK18 ratio levels,
and Log Rank tests. Univariate and multivariate Cox pro-
portional hazard models were used to explore the associ-
ation of markers with disease-free survival. Kaplan Meier
graphs were made with Graphpad Prism (version 4.0,
Graphpad Prism Inc., La Jolla, CA, USA) software.
Results
CK18-Asp396 and total CK18 levels in plasma of colorectal 
cancer patients
Overall the plasma CK18-Asp396 and total CK18 levels
correlated very well with each other, in plasma before, as
well as shortly and longer after tumor resection (overall
Spearman correlation coefficient Rho = 0.64, p < 0.0001).
The CK18-Asp396 and total CK18 plasma values increased
shortly after surgical resection of the tumor and dropped to
about pre-operative values longer after surgery (Table 1).
Correlation pre-operative plasma CK18-Asp396 and CK18 
levels with clinico-pathological patient parameters
The clinico-pathological parameters of the 49 patients are
shown in Table 2. CK18-Asp396 and total CK18 plasma
levels did not correlate with localization of the tumor,
also not within the patients with only colonic tumors (not
shown). Male and female colorectal cancer patients had
similar plasma CK18-Asp396 and total CK18 levels, and
these were not correlated with patients' age. The CK18-
Asp396 and total CK18 plasma values were higher in
patients with more advanced tumor stages (Figure 1A and
1B, p = 0.01 and p = 0.05, respectively). CK18-Asp396 lev-
els correlated with the diameter of the tumor (Spearman
correlation coefficient Rho = 0.35, p = 0.02). Both CK18-
Asp396 and total CK18 levels were significantly higher in
the eight patients with a Dukes' D tumor in which the
tumor was not (or not curatively) resected.
Pre-operative plasma CK18-Asp396 and CK18 levels and 
disease-free survival
The disease-free survival of the patients with low CK18-
Asp396 plasma levels before resection (≤ median) was sig-
nificantly better compared with patients with high CK18-
Asp396 plasma levels (Figure 1C). This was also the case for
total CK18 plasma levels (Figure 1D). When the patients
were subdivided in "early" and "advanced" tumors, Dukes'
A/B stage carcinoma (n = 27) and C/D stage carcinoma (n
= 22), the plasma CK18-Asp396 level was also prognostic
within these subgroups (Figure 1E and 1F). Calculation of
hazard ratios as estimates of relative risk of death or disease
recurrence is shown in Table 3. Tumor progression, CK18-
Asp396 and total CK18 levels in plasma before surgery were
predictive of recurrence or death.
The CK18-Asp396/CK18 ratio indicates the balance
between caspase-mediated apoptosis and non-proteolytic
necrosis. CK18-Asp396/CK18 ratios of pre-operative plas-
mas of colorectal cancer patients were calculated and a
large variety was observed in different patients with a
median ratio of 0.20 (IQR: 0.15–0.26). The CK18-
Asp396/CK18 ratio tended to decrease with increasing
Dukes' stage (Figure 2A), indicating more necrosis over
apoptosis, during tumor progression. The disease-free sur-
vival of patients with high ratios tended to be better when
compared with those with lower ratios (Figure 2B). This
relation was particularly present in patients with Dukes'
Table 1: CK18-Asp396 and total CK18 levels in plasma of CRC patients.
P1 (n = 49) P2 (n = 20) P3 (n = 28)
Mean time to operation (days, range) -13 (-50-0) +20 (7–60) +137 (82–364)
CK18-Asp396 level (U/l)
Median (IQR) 59.1 (41.5–88.2) 74.8 (39.7–107.9) 55.6 (42.1–79.9)
P-value 0.02 vs P1 0.11 vs P2
Total CK18 level (U/l)
Median (IQR) 260.5 (181.6–378.3) 308.1 (208.7–492.3) 257.2 (183.8–457.2)
P-value 0.08 vs P1 0.05 vs P2
CK18-Asp396 and total CK18 levels in plasma of colorectal cancer patients. Wilxocon signed-rank tests were used to compare paired 
observations. P ≤ 0.05 were considered significant, shown in bold. P1 = pre-operative plasma, P2 = post-operative plasma shortly after operation, 
and P3 = post-operative plasma longer after operation.BMC Cancer 2009, 9:88 http://www.biomedcentral.com/1471-2407/9/88
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C/D stage carcinomas (Figure 2C), in contrast to patients
with Dukes' A/B stage carcinomas where no such relation
was found (Figure 2D).
CK18-Asp396, CK18 levels and CK18-Asp396/CK18 ratios 
in post-operative plasma
Post-operative plasma CK18-Asp396 levels of patients
about 4.5 months after resection of Dukes' C/D stage car-
cinomas were also somewhat, but not significantly, higher
compared with patients with Dukes' A/B stage carcinomas
(Figure 3A). The total CK18 plasma levels, however, were
significantly higher in Dukes' C/D tumor patients com-
pared with Dukes' A/B tumor patients (Figure 3B). High
CK18-Asp396 levels as well as total CK18 plasma levels
after tumor resection were associated with worse disease-
free survival (Figure 3C and 3D), also found in the univar-
iate Cox hazard analysis (Table 3).
CK18-Asp396/CK18 ratios in post-operative patients'
plasma were in a similar range as in the patients' plasma
Pre-operative plasma CK18-Asp396 and total CK18 levels, and survival Figure 1
Pre-operative plasma CK18-Asp396 and total CK18 levels, and survival. CK18-Asp396 and total CK18 levels in pre-
operative plasma of all colorectal cancer patients with a Dukes' A/B vs Dukes' C/D stage carcinoma (P1, A and B). Box plots 
with line indicating median value, box indicating IQR and bars indicating the range. Kaplan Meier disease-free survival curves of 
all colorectal cancer patients, groups divided upon median values of CK18-Asp396 (C) and total CK18 levels (D) in pre-opera-
tive plasma (P1). Patients were also subdivided in Dukes' A/B (E, n = 22) and Dukes' C/D (F, n = 27) stage carcinoma.
A/B C/D
0
100
200
300
400
500
Dukes' stage
P
r
e
-
o
p
e
r
a
t
i
v
e
 
p
l
a
s
m
a
 
 
C
K
1
8
-
A
s
p
3
9
6
 
 
(
U
/
L
)
CK18-Asp396 ≤ median
Total CK18 ≤ median
Total CK18 > median
CK18-Asp396 > median
All patients
Pre-operative plasma 
Log Rank 10.84
P=0.001
0 1 2 3 4 5 6 7 8
0
20
40
60
80
100
Time (years)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
%
0 1 2 3 4 5 6 7 8
0
20
40
60
80
100
Time (years)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
%
0 1 2 3 4 5 6 7 8
0
20
40
60
80
100
Time (years)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
%
0 1 2 3 4 5 6 7 8
0
20
40
60
80
100
Time (years)
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
%
C                                                         D
E                                                          F
Dukes’ C/D
Pre-oprative plasma
Log Rank 5.89
P=0.02
Dukes’ A/B
Pre-operative plasma
Log Rank 4.04
P=0.02
A                                                         B
P=0.01 P=0.05
A/B C/D
0
1000
2000
3000
4000
Dukes' stage
P
r
e
-
o
p
e
r
a
t
i
v
e
 
p
l
a
s
m
a
 
 
t
o
t
a
l
 
C
K
1
8
 
 
(
U
/
L
)
All patients
Pre-operative plasma 
Log Rank 5.91
P=0.02
n=27 n=22 n=27 n=22
CK18-Asp396 ≤ median
CK18-Asp396 > median
CK18-Asp396 ≤ median
CK18-Asp396 > medianBMC Cancer 2009, 9:88 http://www.biomedcentral.com/1471-2407/9/88
Page 5 of 10
(page number not for citation purposes)
before surgery, and also tended to decrease with increas-
ing Dukes' stage, i.e., significantly higher in Dukes' A/B
compared with Dukes' C/D patients (Figure 3E). The dis-
ease-free survival was again better in patients with high
post-operative plasma CK18-Asp396/CK18 ratios (Figure
3F).
In 8 of the 28 patients post-operative treatment with radi-
otherapy and in only one patient treatment with com-
bined radio-chemotherapy was started before collection
of the 4.5 months plasma samples. There were no signifi-
cant differences in post-operative plasma CK18-Asp396
and total CK18 levels, and in CK18-Asp396/CK18 ratios
in patients receiving post-operative adjuvant therapy com-
pared to the patients without adjuvant therapy (data not
shown, Additional file 1).
Multivariate Cox regression analysis
A multivariate Cox proportional hazards model of dis-
ease-free survival was used to evaluate whether the plasma
CK18-Asp396 and total CK18 levels showed independent
prognostic significance from tumor staging. These analy-
ses showed that patients with high pre-operative CK18-
Asp396 plasma levels have a 3.6 times increased relative
risk of colorectal cancer-related-death or disease recur-
rence (Table 3), independent of Dukes' staging. For total
CK18 levels, this was quite similar although just not sig-
nificant. Patients with low pre-operative plasma CK18-
Asp396/CK18 ratios had a 2.8 times increased risk to
develop recurrence or death. Post-operative CK18-
Asp396, total CK18 and CK18-Asp396/CK18 ratio levels
all had similar prognostic significance, although not sig-
nificant (Table 3).
Correlation tumor and plasma CK18-Asp396 level
Corresponding colorectal tumor tissue was obtained in 40
cases. CK18-Asp396 levels were significantly (p = 0.05)
higher in tumor tissue when compared with normal adja-
cent tissue with a median value of 2.1 (IQR: 0.3–7.7, n =
40) vs 1.8 (IQR: 0.1–4.2, n = 36) U/mg, respectively.
Tumor CK18-Asp396, total CK18 levels and CK18-
Asp396/CK18 ratios were only found to correlate with
tumor location, with rectal tumors having higher levels
(Table 4). Surprisingly, CK18-Asp396 plasma levels
showed a tendency to inversely correlate with the CK18-
Asp396 level of the tumor (Rho = -0.307, p = 0.054).
Tumor CK18-Asp396, total CK18 levels and CK18-
Asp396/CK18 ratios were found to be not prognostic for
disease-free survival (data not shown, Additional File 2).
Discussion
In the present study we found CK18-Asp396 and total
CK18 levels in plasma from colorectal cancer patients to
be related to patient and tumor characteristics, to change
in relation to tumor resection, and to be a predictor for
disease-free survival. The observation that the death of
tumor cells generates detectable products in the circula-
Table 2: Clinico-pathological characteristics and pre-operative plasma levels
Patient and tumor characteristics No of patients (%)
Total n = 49
Plasma CK18-Asp396 (U/l) 
Median (IQR)
P-value Total CK18 plasma level (U/l) 
Median (IQR)
P-value
Gender 0.87 0.92
Male 31 (63) 61.1 (41.8–88.2) 260.5 (174.1–382.8)
Female 18 (37) 50.5 (37.6–110.2) 252.9 (184.5–352.1)
Age (median 68 year, range 31–84) 0.32 0.38
≤ median 25 (51) 59.1 (15.1–99.0) 288.6 (181.6–403.5)
> median 24 (49) 55.6 (34.2–74.0) 232.4 (177.3–328.6)
Location 0.63 0.25
Colon 38 (78) 59.4 (40.5–102.8) 268.6 (199.7–391.1)
Rectum 11 (22) 56.4 (43.3–68.4) 208.4 (174.1–377.9)
Dukes' stage 0.01 0.05
A/B 27 (55) 49.3 (34.2–67.8) 235.0 (170.5–303.5)
C/D 22 (45) 69.2 (49.7–114.5) 295.8 (202.3–706.3)
WHO classification 0.43 0.56
Adenocarcinoom 45 (92) 59.1 (39.9–82.2) 265.4 (186.7–378.3)
Mucinous carcinoom 4 (8) 77.8 (48.9–177.7) 211.2 (172.0–363.1)
Tumor diameter (median 4.5 cm, 
range 2–13.5)*
0.03 0.07
≤ median 24 (55) 49.1 (31.9–67.7) 232.4 (174.5–187.7)
> median 20 (45) 64.7 (43.7–133.3) 287.3 (180.0–657.6)
Surgery 0.001 <0.001
Yes, curative resection 41 (84) 51.1 (36.5–73.7) 235.0 (172.3–331.9)
No, or palliative 8 (16) 162.9 (68.8–346.4) 971.7 (306.1–2290.4)
Clinico-pathological characteristics and pre-operative CK18-Asp396 and total CK18 plasma levels. P-values were calculated with Kruskal-Wallis and 
Mann-Whitney tests and P ≤ 0.05 were considered significant, shown in bold. * Some values missing.BMC Cancer 2009, 9:88 http://www.biomedcentral.com/1471-2407/9/88
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tion of cancer patients is interesting for diagnostics pur-
poses and monitoring therapy that induces tumor cell
death. Cytokeratins are abundantly present in epithelial
cells and their expression is usually retained or even
increased after oncogenic transformation [15]. CK18 is
cleaved by caspase-3 during apoptosis, resulting in the
release of the degraded CK18-Asp396 product, i.e., the
M30 antigen, into the circulation. It has previously been
shown that circulating CK18-Asp396 levels are elevated in
patients with various epithelial cancer types and to be
increased during chemotherapy [8,9,13].
The CK18-Asp396 and total CK18 levels in the plasma of
colorectal cancer patients, before and after surgical resec-
tion of the tumor, correlated very well with each other, as
expected, because the CK18 ELISA recognizes the soluble
fragments of CK18 that are detected in the M30 ELISA, as
well as other soluble non-caspase cleaved CK18 frag-
ments. Both CK18-Asp396 and total CK18 plasma values
increased shortly after surgical resection of the tumor,
likely due to the surgical procedure. Because the apoptotic
cells are randomly distributed throughout colorectal car-
cinomas [16], it is evident that products of apoptotic
tumor cells do not all enter the circulation of these
patients but are also released into the lumen and leave the
body via stool, especially in tumors that have not invaded
and spread to adjacent lymph nodes. Our results showed
a correlation between CK18-Asp396 and total CK18
plasma levels and colorectal tumor stage, confirming that
patients with advanced disease have higher CK18-Asp396
Table 3: Univariate and multivariate Cox regression analysis
Patient and tumor characteristics Univariate Hazard Ratio 
(95% confidence interval)
P-value Multivariate Hazard Ratio 
(95% confidence interval)
P-value
Gender 0.27
Female 1 (ref)
Male 1.79 (0.64–497)
Age (median 68 year) 0.83
≤ median 1 (ref)
> median 1.10 (0.45–2.73)
Location 0.32
Colon 1 (ref)
Rectum 0.54 (0.16–1.85)
Dukes' stage <0.001 <0.001–0.021
A/B 1 (ref) 1(ref)
C/D 8.21 (2.70–24.97) 6.01–9.60 (1.32–33.31)
Tumor diameter (median 4.5 cm) 0.32
≤ median 1 (ref)
> median 1.68 (0.61–4.65)
WHO classification 0.82
Adenocarcinoom 1 (ref)
Mucinous carcinoom 0.79 (0.11–5.90)
CK18-Asp396 plasma level P1 0.003 0.03
≤ median 1 (ref) 1 (ref)
> median 5.28 (1.75–15.92) 3.58 (1.17–11.02)
Total CK18 plasma level P1 0.02 0.055
≤ median 1 (ref) 1 (ref)
> median 3.30 (1.19–9.16) 3.58 (0.97–7.71)
CK18-Asp396/CK18 ratio P1 0.12 0.04
≤ median 2.09 (0.82–5.31) 2.78 (1.06–7.19)
> median 1 (ref) 1 (ref)
CK18-Asp396 plasma level P3 0.054 0.10
≤ median 1 (ref) 1 (ref)
> median 4.71 (0.97–22.85) 3.78 (0.77–18.50)
Total CK18 plasma level P3 0.055 0.08
≤ median 1 (ref) 1 (ref)
> median 4.69 (0.97–22.72) 4.12 (0.84–20.34)
CK18-Asp396/CK18 ratio P3 0.04 0.10
≤ median 5.28 (1.08–25.72) 3.96 (0.78–20.08)
> median 1 (ref) 1 (ref)
Cox hazards analysis of patient and tumor characteristics in relation to disease-free survival. Multivariate Cox hazards analysis of pre-operative or 
post-operative CK18-Asp396, total CK18 antigen level or CK18-Asp396/CK18 ratios combined with Dukes' stage. P ≤ 0.05 were considered 
significant, shown in bold.BMC Cancer 2009, 9:88 http://www.biomedcentral.com/1471-2407/9/88
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and total CK18 levels. The positive correlation of CK18-
Asp396 plasma levels with tumor diameter further sup-
ports that the plasma levels are indeed elevated due to the
presence of the tumor, with larger tumors responsible for
more antigen "secretion". Because we found no correla-
tion between tumor diameter or Dukes' stage with CK18-
Asp396 level within the tumor, these parameters might be
the cause of the inverse correlation between CK18-Asp396
plasma levels and CK18-Asp396 atumor levels. Taken
together these results strongly indicate that CK18-Asp396
and total CK18 levels are reflected in the plasma of color-
ectal cancer patient due to the presence of the tumor.
CK18-Asp396 plasma levels were related to patient's out-
come, independent from Dukes' stage, with patients with
higher levels having worse disease-free survival. These
Pre-operative plasma CK18-Asp396/CK18 ratios and survival Figure 2
Pre-operative plasma CK18-Asp396/CK18 ratios and survival. Pre-operative plasma CK18-Asp396/CK18 ratios 
decrease with increasing Dukes' stage (P1, A). Box plots with line indicating median value, box indicating IQR and bars indicat-
ing the range. Kaplan Meier disease-free survival curves of all colorectal cancer patients, groups divided upon median pre-oper-
ative plasma CK18-Asp396/CK18 ratios (B). Patients were also subdivided in Dukes' C/D (C, n = 22) and Dukes' A/B stage 
carcinoma (D, n = 27).
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observations are comparable to the reports about CK18-
Asp396 levels in sera of patients with breast and lung cancer
[8,9]. Patients with recurrent breast cancer also had highest
CK18-Asp396 levels in their circulation and there was a cor-
relation with the number of organs affected, suggesting
increased CK18-Asp396 levels in the circulation associated
with cancer progression [8], which concurs with our obser-
vation of a relation with Dukes' stage. Patients with lung
cancer also had increased serum levels of CK18-Asp396,
and patients with the lowest basal CK18-Asp396 levels
showed the best survival [9]. Moreover, CK18-Asp396 and/
or total CK18 levels were found to be increased due to
chemotherapy in lung, prostate and breast cancer patients,
showing the induction of tumor cell death [9-11,13]. In
Post-operative CK18-Asp396, total CK18 and CK18-Asp396/CK18 ratios levels, and survival Figure 3
Post-operative CK18-Asp396, total CK18 and CK18-Asp396/CK18 ratios levels, and survival. Post-operative (P3) 
CK18-Asp396 and total CK18 levels of colorectal cancer patients with a Dukes' A/B vs Dukes' C/D stage carcinoma (A and B). 
Box plots with line indicating median value, box indicating IQR and bars indicating the range. Kaplan Meier disease-free survival 
curves of all colorectal cancer patients, groups divided upon median post-operative CK18-Asp396 (C, n = 28) and total CK18 
levels (D, n = 28). Plasma CK18-Asp396/CK18 ratios were decreased in patients Dukes' C/D vs Dukes' A/B (E). Kaplan Meier 
disease-free survival curves of colorectal cancer patients, groups divided upon median post-operative plasma CK18-Asp396/
CK18 ratios (F, n = 28).
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addition, the increase in total CK18 levels in breast cancer
patients correlated with clinical response to therapy and
survival. Thus, circulating CK18-Asp396 and total CK18
levels could potentially be used to monitor treatment effi-
cacy in cancer patients. However, we did not find a relation
between post-operative plasma CK18-Asp396 and/or total
CK18 levels, in the plasmas obtained about 4.5 months
after surgical intervention, and the post-operative adjuvant
treatment the patients received, that started already within
1 month after surgery. Apparently, plasma CK18-Asp396
and/or total CK18 levels in colorectal cancer patients are
intrinsically related to the tumor and less indicative for
treatment response.
The ratio between plasma CK18-Asp396 and total CK18
levels reflects differences in apoptosis and necrosis, and
might reflect tumor-related differences in those two cell
death modes. Necrosis is believed to be a major process in
hypoxic tumors as it does not need ATP to be executed, in
contrast to apoptosis. Furthermore, hypoxia blocks apop-
tosis and contributes to treatment resistance [17,18].
Therefore, plasma CK18-Asp396/CK18 ratios can poten-
tially be used to predict the response and determine which
patients should be treated aggressively. In the present
study, the CK18-Asp396/CK18 ratio tended to lower with
increasing Dukes' stage, indicating that necrosis increases
more than apoptosis during tumor progression, similar as
reported for endometrial cancer [11]. High levels of necro-
sis in more advanced tumor stages fits with the idea that
hypoxia forces the tumor to form new blood-vessels and
to invade the muscularis mucosa to reach the circulation
for oxygen supply, finally resulting in more advanced
tumor stages [19,20]. Decreased plasma CK18-Asp396/
CK18 ratios during tumor progression, furthermore, fit
with the idea that there is a decrease in apoptotic sensitiv-
ity of tumor cells during colorectal tumor progression
[16]. Interestingly, the patients CK18-Asp396 plasma lev-
els and CK18-Asp396/CK18 ratios after tumor resection
are also of prognostic relevance for the patient's disease-
free survival. Both post-operative plasma CK18-Asp396
and CK18-Asp396/CK18 ratios were independent of the
post-operative treatment the patients received. Thus,
determination of plasma CK18-Asp396 and CK18-
Asp396/CK18 ratios might also be a powerful independ-
ent tool to monitor patients after resection. In order to be
conclusive, however, these interesting preliminary obser-
vations, due to the limited power of our study with only
49 colorectal cancer patients, merit further evaluation in
larger patient groups.
Conclusion
CK18-Asp396 and total CK18 levels in the circulation of
colorectal cancer are prognostic for disease-free survival
independent of disease stage, and might be helpful to
select patient's treatment and in monitoring the patient
after surgery, which should be confirmed in larger pro-
spective studies.
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Table 4: Clinico-pathological characteristics and tumor levels
Patient and tumor 
characteristics
No of patients (%) 
Total n = 40
CK18-Asp396 level (U/
mg) Median (IQR)
P-value Total CK18 level (U/mg) 
Median (IQR)
P-value CK18-Asp396/CK18 × 
100 Median (IQR)
P-value
Gender 0.94 0.67 0.96
Male 26 2.1 (0.2–7.7) 203.0 (64.0–318.2) 1.9 (0.3–3.7)
Female 14 1.3 (0.2–10.3) 159.0 (33.2–273.5) 1.7 (0.2–3.6)
Age (median 68 year) 0.98 0.29 0.77
≤ median 20 1.4 (0.3–6.1) 165.0 (53.0–331.7) 1.8 (0.5–3.4)
> median 20 2.2 (0.2–9.7) 219.1 (57.0–248.9) 2.2 (0.2–3.8)
Location 0.003 0.03 0.005
Colon 32 0.8 (0.2–5.7) 147.0 (47.1–243.3) 1.4 (0.2–2.4)
Rectum 8 12.7 (3.5–19.5) 291.5 (214.6–369.7) 3.7 (2.8–6.3)
Dukes' stage 0.79 0.49 0.90
A/B 25 1.6 (0.3–9.7) 177.1 (71.8–310.2) 1.8 (0.2–3.4)
C/D 15 1.3 (0.1–5.9) 222.4 (32.7–252.1) 2.0 (0.4–3.8)
WHO classification 0.90 0.49 0.94
Adenocarcinoom 37 1.6 (0.3–7.7) 190.3 (56.9–281.9) 1.9 (0.3–3.4)
Mucinous 
carcinoom
3 1.1 65.4 1.7
Tumor diameter 
(median 4.5 cm)*
0.37 0.43 0.31
≤ median 20 4.3 (0.3–10.3) 203.0 (56.9–310.2) 2.3 (0.3–3.9)
> median 18 1.3 (0.1–5.7) 154.0 (36.7–281.9) 1.6 (0.2–2.3)
Clinico-pathological characteristics and tumor CK18-Asp396, total CK18 and CK18-Asp396/CK18 ratios. P-values were calculated with Kruskall-
Wallis and Mann-Whitney tests and P ≤ 0.05 were considered significant, shown in bold. * Some values missing.Publish with BioMed Central    and   every 
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